Prostate cancer therapy: going forwards by going backwards
Mené sur 192 patients atteints d'un cancer métastatique de la prostate, cet essai multicentrique de phase III (29 centres français, 1 centre belge) évalue, du point de vue de la survie globale, l'ajout de docétaxel à un traitement antiandrogénique
In The Lancet Oncology, Gwenaelle Gravis and colleagues present the results of a phase 3 trial assessing the combination of docetaxel and androgen-deprivation therapy (ADT) for patients with metastatic non-castrate (ie, hormone-sensitive) prostate cancer. The premise underlying this study is that an agent with clinical benefit in castrate-resistant prostate cancer might prolong the lives of men with metastatic prostate cancer if used before the disease becomes insensitive to hormones...
The Lancet Oncology , commentaire en libre accès, 2012